Management of Moderate-to-Highly Exuding Chronic Leg Ulcers With Superabsorbent Wound Dressings Versus Foams Dressings in Polish Settings: An Early-Stage Cost-Effectiveness Evaluation.

The study is a model-based economic evaluation, not a trial that observed real patients receiving the dressings. It is described as an early health technology assessment using preliminary non-randomized clinical efficacy data. The model relies on published data and clinical trial inputs, which may not capture individual patient experiences. The 6-month horizon does not cover long-term outcomes or recurrence. Transition probabilities came from different studies and were not perfectly matched to the same age, comorbidities, and medication profiles. Patients, the public, communities, and payers were not involved in the study design. Wounds were not stratified by classification or severity beyond moderate-to-highly exuding chronic leg ulcers. Diabetic foot ulcers were excluded, so results do not apply to that population. Distributional effects were not characterized because of limited data. The 2% healing difference is a modelled projection, not a directly observed patient outcome.

The funding section states the authors have nothing to report. Vladica Veličković and Anna Serafin are employees of HARTMANN GROUP and may have competing interests; the other two authors declare no conflicts of interest.

Do not read this as proof that SAP dressings heal more ulcers or save money in your own patients. It is a model based on existing data, the healing difference was not directly observed, and authors from the dressing manufacturer are involved.